Sökresultat - Martin Grießhammer

Förfina resultatet
  1. 1
    Current and future treatment options for polycythemia vera

    Current and future treatment options for polycythemia vera av Martin Grießhammer, Heinz Gisslinger, Ruben A. Mesa

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  2. 2
    Thromboembolic events in polycythemia vera

    Thromboembolic events in polycythemia vera av Martin Grießhammer, Jean‐Jacques Kiladjian, Carlos Besses

    Publicerad 2019
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Plasma Fibrin D-Dimer Levels and Risk of Stable Coronary Artery Disease

    Plasma Fibrin D-Dimer Levels and Risk of Stable Coronary Artery Disease av Wolfgang Köenig, Dietrich Rothenbacher, Albrecht Hoffmeister, Martin Grießhammer, Hermann Brenner

    Publicerad 2001
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  4. 4
    Subtyping non-small cell lung cancer by histology-guided spatial metabolomics

    Subtyping non-small cell lung cancer by histology-guided spatial metabolomics av Judith Martha Neumann, Hinrich Freitag, Jasmin Saskia Hartmann, Karsten Niehaus, Michail Galanis, Martin Grießhammer, Udo Kellner, Hanna Bednarz

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  5. 5
    Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

    Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safe... av Gunnar Birgegård, Carlos Besses, Martin Grießhammer, Luigi Gugliotta, Claire Harrison, Mohamed Hamdani, Jingyang Wu, Heinrich Achenbach, Jean‐Jacques Kiladjian

    Publicerad 2017
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease

    Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease av Markus Bangerter, Florian Moog, Inga Buchmann, J. Kotzerke, Martin Grießhammer, Matthias Häfner, Klaus Elsner, Norbert Frickhofen, S. N. Reske, Lothar Bergmann

    Publicerad 1998
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

    Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study av Alessandro M. Vannucchi, Srđan Verstovšek, Paola Guglielmelli, Martin Grießhammer, Timothy C. Burn, Ahmad Naim, Dilan Paranagama, Mahtab Marker, Brian Gadbaw, Jean‐Jacques Kiladjian

    Publicerad 2017
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  8. 8
    Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study

    Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study av Francesco Passamonti, Francesca Palandri, Güray Saydam, Jeannie Callum, Timothy Devos, Paola Guglielmelli, Alessandro M. Vannucchi, Evren Zor, Mike W. Zuurman, Geralyn Gilotti, Yifan Zhang, Martin Grießhammer

    Publicerad 2022
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

    Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial av Martin Grießhammer, Güray Saydam, Francesca Palandri, Giulia Benevolo, Miklós Egyed, Jeannie Callum, Timothy Devos, Serdar Şıvgın, Paola Guglielmelli, Caroline Bensasson, Md Mahmudul Hasan Khan, Julian Perez Ronco, Francesco Passamonti

    Publicerad 2018
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  10. 10
    How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024

    How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024 av Martin Grießhammer, Haifa Kathrin Al‐Ali, Jan‐Niklas Eckardt, Michael Fiegl, Joachim R. Göthert, Kathleen Jentsch‐Ullrich, Steffen Koschmieder, Hans Michael Kvasnicka, Andreas Reiter, Burkhard Schmidt, Florian H. Heidel

    Publicerad 2025
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  11. 11
    Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

    Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference av Giovanni Barosi, Gunnar Birgegård, Guido Finazzi, Martin Grießhammer, Claire Harrison, Hans Carl Hasselbalch, Jean‐Jacques Kiladjian, Eva Lengfelder, Mary Frances McMullin, Francesco Passamonti, John T. Reilly, Alessandro M. Vannucchi, Tiziano Barbui

    Publicerad 2009
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

    A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group av Giovanni Barosi, Carlos Besses, Gunnar Birgegård, J Brière, Francisco Cervantes, Guido Finazzi, Heinz Gisslinger, Martin Grießhammer, L Gugliotta, Claire Harrison, Hans Carl Hasselbalch, Eva Lengfelder, John T. Reilly, Jan Michiels, Tiziano Barbui

    Publicerad 2006
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  13. 13
    Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study

    Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study av Vikas Gupta, Martin Grießhammer, Bruno Martino, Lynda Foltz, Renato Tavares Daher, Haifa Kathrin Al‐Ali, Pilar Giraldo, Paola Guglielmelli, Elza Lomaia, Catherine Bouard, Carole Paley, Ranjan Tiwari, Evren Zor, Pia Raanani

    Publicerad 2020
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  14. 14
    Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

    Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosi... av Francesco Passamonti, Vikas Gupta, Bruno Martino, Lynda Foltz, Andrey Zaritskey, Haifa Kathrin Al‐Ali, Renato Tavares Daher, Margherita Maffioli, Pia Raanani, Pilar Giraldo, Martin Grießhammer, Paola Guglielmelli, Catherine Bouard, Carole Paley, Ranjan Tiwari, Alessandro M. Vannucchi

    Publicerad 2021
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  15. 15
    FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

    FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of th... av Susanne Isfort, Nikolas von Bubnoff, Haifa Kathrin Al‐Ali, Heiko Becker, Thorsten Oliver Götze, Philipp le Coutre, Martin Grießhammer, Claudia Moskwa, Luisa Wohn, Johanna Riedel, Francesca Palandri, Kirsi Manz, Andreas Hochhaus, Konstanze Döhner, Florian H. Heidel

    Publicerad 2024
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  16. 16
    Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

    Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera av Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Ruben A. Mesa, Shui He, Mark M. Jones, William M. Garrett, Jingjin Li, Ulrich Pirron, Dany Habr, Srđan Verstovšek

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  17. 17
    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy av Ruben A. Mesa, Srđan Verstovšek, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Hui‐Ling Zhen, Mark M. Jones, Shreekant Parasuraman, Jingjin Li, Isabelle Côté, Dany Habr, Alessandro M. Vannucchi

    Publicerad 2015
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  18. 18
    Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

    Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP... av Haifa Kathrin Al‐Ali, Martin Grießhammer, Philipp le Coutre, Cornelius F. Waller, A. M. Liberati, Philippe Schafhausen, Renato Tavares Daher, Pilar Giraldo, Lynda Foltz, Pia Raanani, Vikas Gupta, Bayane Tannir, Julian Perez Ronco, Jaya Ghosh, B. Martino, Alessandro M. Vannucchi

    Publicerad 2016
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  19. 19
    Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation

    Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation av Peter J. Campbell, E. Joanna Baxter, Philip Beer, Linda M. Scott, Anthony J. Bench, Brian J.P. Huntly, Wendy N. Erber, Rajko Kušec, Thomas Stauffer Larsen, Stéphane Giraudier, Marie‐Caroline Le Bousse‐Kerdilès, Martin Grießhammer, John T. Reilly, Betty Cheung, Claire Harrison, Anthony R. Green

    Publicerad 2006
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  20. 20
    Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis

    Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis av Renato Tavares Daher, Giuseppe A. Palumbo, Philipp le Coutre, Francesca Palandri, Haifa Kathrin Al‐Ali, Bruno Martino, Anna Marina Liberati, José María Grasa, Massimo Breccia, David Brittain, Lynda Foltz, Martin Grießhammer, Pia Raanani, Vikas Gupta, Pilar Giraldo, Jagannath Ghosh, Bayane Tannir, Julian Perez Ronco, Alessandro M. Vannucchi

    Publicerad 2015
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: